BFC Planning, Inc.’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
BFC Planning, Inc.'s RXRX Position: Q2 2026 in Review
BFC Planning, Inc. increased its Recursion Pharmaceuticals (RXRX) stake by 32% in Q2 2026, buying an estimated $6.81K and bringing the position to 8,399 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1786.
BFC Planning, Inc. first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $42.4K in Q3 2025. 346 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- BFC Planning, Inc. held 8,399 shares of Recursion Pharmaceuticals worth $30.8K as of Q2 2026.
- BFC Planning, Inc. bought 2,045 Recursion Pharmaceuticals shares in Q2 2026, an estimated $6.81K.
- Recursion Pharmaceuticals made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #1786 holding.
- BFC Planning, Inc. first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
- BFC Planning, Inc.'s Recursion Pharmaceuticals position peaked at $42.4K in Q3 2025.
- 346 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.